FDI is following the same currents that shape pharma services: biologics substance, sterile fill-finish, and device/containment. Capital alone doesn’t move the needle—deployment into platforms, people, and pipelines does.
Executive summary
FDI in Indian pharma continues to expand, with a tilt toward high-growth modalities and bottleneck removal: biologics, injectables, and device/containment components. Winners translate funding into platform capabilities, not one-off projects.
- Clear demand (injectables, large modalities)
- Permitting and EHS readiness
- Digital QA and documentation maturity
- Supplier depth and logistics access
Where the funds land
| Area | Rationale | Common upgrades |
|---|---|---|
| Biologics drug substance | Fast CAGR, technical moat | Single-use trains, analytics |
| Sterile fill-finish | Capacity constraints | Isolators, automation, visual inspect |
| Device/containment | GLP-1 & injectables surge | Precision molding, QA |
| Analytical services | Pipeline complexity | Methods dev, digital labs |
Facilities that convert capex into performance do three things well: standardize data, automate compliance, and hire for systems thinking.
Regions and market access
Export Performance by Region
EU lanes favor faster approvals for compliant operators. US lanes demand deeper documentation but yield premium access. APAC adds volume with mixed compliance depth.
Operator playbook for deployed capital
- Lock master data model before equipment hits the floor
- Stand up EBR + deviation analytics with change control
- Score suppliers; pre-qualify alternates
- Publish documented escalation paths for exceptions
Measuring what matters
| KPI | Top quartile | Median | Notes |
|---|---|---|---|
| Capex to capacity (months) | 8–12 | 12–18 | Lead time from funding to throughput |
| First-pass QA acceptance | 98–99% | 96–97% | Quality maturity proxy |
| EBR coverage | 90–100% | 60–80% | Predictability and speed |
| OTIF | 95–97% | 92–94% | Customer trust and access |